Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
246 participants
INTERVENTIONAL
2018-06-30
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Automatic Segmentation of Polycystic Liver
NCT03960710
Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB
NCT06616103
Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI
NCT06037343
Low Contrast Agent and Radiation Dose Protocol for Liver CT in Patients With HCC
NCT04722120
Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning
NCT05257694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liver from deceased donors
This study included all consecutive subjects with chronic liver disease who underwent LT for the first time with a deceased donor liver
Liver from deceased donors
Liver donors photographed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liver from deceased donors
Liver donors photographed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Donor after cardiac death
* Split
* Cholestasis due to a biliary obstruction
* Total bilirubin levels above 2,5 mg/dL
* Glutamic oxaloacetic transaminase (SGOT)/ serum glutamatepyruvate transaminase (SGPT) levels and gamma-glutamyl transaminase (GGT) levels above 400 U/L
* Cirrhotic livers
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Vall d'Hebron
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Concepción Gomez Gavara
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Concepcion Gómez-Gavara, PhD
Role: PRINCIPAL_INVESTIGATOR
Vall D´Hebron University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Concepción Gómez-Gavara
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR(AG)04/2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.